40054-40-8

Usage

Uses

Used in Pharmaceutical Industry:
5-(O-CHLOROPHENYL)-7-ETHYL-1,2-DIHYDRO-3H-THIENO[2,3-E][1,4]DIAZEPINE-2-THIONE is used as a sedative, anxiolytic, and muscle relaxant for the treatment of anxiety, insomnia, and other central nervous system disorders. Its pharmacological properties make it a promising candidate for the development of new therapeutic agents to address these conditions.
Used in Research and Development:
5-(O-CHLOROPHENYL)-7-ETHYL-1,2-DIHYDRO-3H-THIENO[2,3-E][1,4]DIAZEPINE-2-THIONE is used in research and development for exploring its potential therapeutic applications, including anticonvulsant and hypnotic properties. Further studies are needed to understand its safety profile and optimize its use in various medical conditions.

Upstream product

• 33671-37-3 5-(2-Chlorophenyl)-7-ethyl-1,3-dihydro-2H-thieno[2,3-e]1,4-diazepin-2-one 

Downstream Products

• 67727-30-4 5-(2-chloro-phenyl)-7-ethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one propionylhydrazone 
• 41740-71-0 5-(2-chloro-phenyl)-7-ethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one benzoylhydrazone 
• 54905-10-1 1-[4-(2-chloro-phenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-ethanone 
• 40054-85-1 2-ethyl-4-(2-chloro-phenyl)-9-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 58066-32-3 4-(2-chloro-phenyl)-2,9-diethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 40054-72-6 5-(2-chloro-phenyl)-7-ethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one acetylhydrazone 
• 40054-69-1 etizolam 
• 40054-68-0 4-(2-chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 

Relevant academic research and scientific papers

Therapeutic agent for osteoporosis and diazepine compound

A therapeutic agent for osteoporosis, comprising an azepine compound of the formula STR1 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.

THIENODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF

A thienodiazepine compound represented by general formula (I), a salt thereof, and a medicinal use thereof, wherein R3 represents a group represented by any of the following formulae: (1),-(CH?) aN(R?)COR? (2),-(CH?)aN(R?)SO?R? (3),-(CH?)aN(R?)COOR1? (4),

Syntheses and structure-activity relationships of 6-Aryl-4H-s-triazolo[3,4-c]thieno[2,3-e][1,4]diazepines

A variety of 6 aryl 4H s triazolo [3,4-c]thieno [2,3-e] [1,4]diazepines was synthesized and tested for anti-pentylenetetrazole activity and inhibition of fighting episodes. The structure-activity relationships are discussed. Some compounds were more active than diazepam in the two assays. Among them, 6 (o chlorophenyl) 8 ethyl 1 methyl 4H s triazolo [3,4-c] thieno [2,3-e][1,4] diazepine was found to have favourable properties as an anxiolytic drug with very low toxicity. Clinical studies of this compound (Y-7131) are under way.

Triazolothienodiazepine compounds

Triazolothienodiazepine compounds of the formula; SPC1 Wherein X is a member selected from the group consisting of a hydrogen atom, a methyl group, a methoxy group and a trifluoromethyl group; each of R1 and R2 is a member selected from the group consisting of a hydrogen atom and an alkyl group having 1 to 4 carbon atoms, or R1 and R2 together can form a tetramethylene group, i.e.--(CH2)4 --; R is a member selected from the group consisting of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, --CONHR3 (R3 being an alkyl group having 1 to 4 carbon atoms) and -alk-N(R 4)(R5) (each of R4 and R5 being a member selected from the group consisting of a hydrogen atom and an alkyl group having 1 to 4 carbon atoms, or R4 and R5 and N can form a heterocyclic ring; and alk being an alkylene group having 2 to 4 carbon atoms); and Z is a member selected from the group consisting of an oxygen atom and a sulphur atom; and the pharmaceutically acceptable acid addition salts thereof are disclosed. These compounds are useful as minor tranquillizers (anti-anxiety drugs), sleep inducers, and anti-epileptics.